Company profile
Gene editing and gene modulation for life sciences
Horizon Discovery drives the application of gene editing and gene modulation to enable world-leading academic institutes, pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories, to identify the genetic drivers behind human disease, develop and validate diagnostic workflows, and deliver new therapies for precision medicine. With more than a decade of experience in the engineering of cell lines, Horizon offers innovative tools and services based upon the ability to modulate, or permanently alter, the function of almost any gene in human and other mammalian cell lines. Horizon is headquartered in Cambridge, UK with offices in USA and Japan.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
CERTNM | Transaction MzQzNjE2MTc3OWFkaXF6a2N4
Published 17 Sep 2024 06:57
Company registered at Companies House
1 May 2024 to 30 Sep 2026
Cell and gene therapies are promising treatments for several unmet medical needs. Most of these therapies rely on viral vectors as the delivery tool for cell modification. HEK-293 cell line is the most used platform for the manufacturing of cell and gene therapy viral vectors that have achieved successful clinical data and regulatory approval for commerci...
1 Dec 2018 to 31 Aug 2021
"Non-invasive prenatal testing (NIPT), the analysis of cell-free fetal DNA (cffDNA) from the maternal blood, has proven to be more reliable in detecting common fetal trisomies than conventional serum screening and ultrasound. Due to the higher accuracy of NIPT, fewer pregnant woman will have to undergo diagnostic invasive testing which carries a risk of m...
1 Jul 2017 to 31 Oct 2020
Genetic engineering (GE) is an established tool for R&D and promises to become a globally used approach to correct and treat important diseases, such as cancer and genetic disease, and also able to tackle and solve important environmental issues. Current approaches are dependent upon manual labour and extensive screening, and are highly inefficient and ti...
1 Apr 2017 to 30 Apr 2019
The aim of this project is to establish new and innovative approaches for the manufacture of high-value, genome-edited cell lines used in bio-medical research. Genome editing is rapidly becoming an essential tool in all segments of life sciences R&D, from basic research to drug discovery and diagnostics, therapeutics (incl. regenerative medicine), synthet...
1 May 2015 to 30 Nov 2018
This project will deliver a pipeline of engineered Chinese Hamster Ovary (CHO) cells with characteristics and performance that will enable improved manufacture of novel biologic products. Recent research has identified critical metabolic check points that control CHO cell growth, and characterised pathways controlling product integrity and yield. In this ...
1 Jul 2014 to 31 Mar 2016
This project will deliver innovative products that drive the development of enhanced analytical systems to meet the changing needs of diagnosis and stratification of cancer patients. This will allow patients to benefit from recent advances in molecular pathology by delivering more reliable and earlier diagnosis, personalized therapies and disease monitori...
1 Jan 2012 to 28 Feb 2013
Awaiting Public Project Summary
1 Jan 2012 to 28 Feb 2013
Awaiting Public Project Summary
